Organization
Sciwind Biosciences APAC
3 clinical trials
Clinical trial
Safety and Efficacy of Inhaled XW001 (Interleukin 29 Analog for Nebulization) For Hospitalized COVID-19 Patients Requiring Oxygen Therapy: A Multiregional, Randomized, Double-blind, Placebo-controlled StudyStatus: Withdrawn, Estimated PCD: 2022-03-10
Clinical trial
A Phase 2, Open-label, Randomised, Dose-Finding Study of XW003, Once-Weekly Human Glucagon-Like Peptide 1 Analogue, Compared With Once-Daily Liraglutide 3 mg in Adult Participants With ObesityStatus: Completed, Estimated PCD: 2022-11-16
Clinical trial
A Phase 1, Randomised, Double-blind, Placebo-controlled, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Oral Ecnoglutide Tablet in Healthy Adult ParticipantsStatus: Recruiting, Estimated PCD: 2024-07-01